Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations

NCT02982889 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Pain

Interventions

DRUG: LIQ865A bupivacaine formulation
DRUG: LIQ865B bupivacaine formulation
DRUG: Diluent for LIQ865
DRUG: 0.5% bupivacaine hydrochoride

Sponsor

Liquidia Technologies, Inc.

Collaborators

[object Object]